TradeOrgs
  • šŸ‡®šŸ‡³ India
  • šŸ‡ŗšŸ‡ø US
  • Screener
  • Backtest
  • Watchlist
  • Signals
  • Portfolio
  • Insights
  • Connect
Sign in
RELIANCE₹1,218.00ā–¼ 7.87%TCS₹2,100.00ā–¼ 8.85%HDFCBANK₹711.45ā–¼ 0.09%ICICIBANK₹1,342.80ā–¼ 5.65%INFY₹1,013.85ā–¼ 10.28%HINDUNILVR₹1,895.20ā–¼ 3.96%ITC₹266.70ā–² 0.98%SBIN₹958.75ā–¼ 5.64%BHARTIARTL₹1,810.50ā–¼ 1.60%KOTAKBANK₹431.90ā–² 1.74%LT₹3,770.00ā–¼ 4.90%AXISBANK₹1,248.00ā–¼ 1.96%ASIANPAINT₹2,424.20ā–¼ 4.08%MARUTI₹11,625.00ā–¼ 8.42%AAPL$333.63ā–² 4.27%MSFT$529.30ā–² 5.92%GOOGL$347.68ā–² 2.72%AMZN$256.29ā–¼ 0.86%NVDA$239.24ā–² 3.85%META$738.88ā–² 19.80%TSLA$380.68ā–² 7.51%BRK-B$505.54ā–¼ 0.10%JPM$331.28ā–¼ 7.63%V$370.64ā–¼ 1.18%
RELIANCE₹1,218.00ā–¼ 7.87%TCS₹2,100.00ā–¼ 8.85%HDFCBANK₹711.45ā–¼ 0.09%ICICIBANK₹1,342.80ā–¼ 5.65%INFY₹1,013.85ā–¼ 10.28%HINDUNILVR₹1,895.20ā–¼ 3.96%ITC₹266.70ā–² 0.98%SBIN₹958.75ā–¼ 5.64%BHARTIARTL₹1,810.50ā–¼ 1.60%KOTAKBANK₹431.90ā–² 1.74%LT₹3,770.00ā–¼ 4.90%AXISBANK₹1,248.00ā–¼ 1.96%ASIANPAINT₹2,424.20ā–¼ 4.08%MARUTI₹11,625.00ā–¼ 8.42%AAPL$333.63ā–² 4.27%MSFT$529.30ā–² 5.92%GOOGL$347.68ā–² 2.72%AMZN$256.29ā–¼ 0.86%NVDA$239.24ā–² 3.85%META$738.88ā–² 19.80%TSLA$380.68ā–² 7.51%BRK-B$505.54ā–¼ 0.10%JPM$331.28ā–¼ 7.63%V$370.64ā–¼ 1.18%

TradeOrgs shows market information and analyzes your own trading history. It does not place trades and is not investment advice.

Prices and listings are for information only. We are read-only against your broker account.

Technical signals (RSI, MACD, etc.) are educational readouts of public indicators — not recommendations.

Privacy PolicyĀ·Ā© 2026 TradeOrgs

← US stocks

šŸ‡ŗšŸ‡øABOS

Acumen Pharmaceuticals, Inc. - Common Stock

NASDAQ
$2.03
ā–¼ $1.15 (-36.2%)
LiveĀ· just now
delayed feed Ā· not for order timing

Price history Ā· 20-day (cyan) / 50-day (purple) avg

as of 06 Oct 2026
H $3.34L $2.00-7.3%
$3.34$3.07$2.8$2.54$2.27$2$2.03
RSI (14)
Intraday Ā· 15-minStrong sell-50RSI 45DowntrendMACD Bearishfor day-trading context — not advice

Technical signal

Strong sell-60
RSI (14)32
oversold 30overbought 70
Trend
Downtrend
MACD
Bearish
Bollinger
Within bands
vs 20-day
below
vs 50-day
below
vs 200-day
below
Support
$2.00
Resistance
$3.16
  • Price is below its 50-day average (medium-term weakness).

Educational technical indicators — not investment advice. TradeOrgs does not place trades.

Signal backtest Ā· 2026-01-02 → 2026-10-06

Strategy return
-19.1%
Buy & hold
+0.5%
Trades
9
Win rate
11%

$100,000.00 invested would be worth $80,874.84 (-19.1%) Ā· Full backtester →

Hypothetical: go long when the signal turns Buy, exit when it turns Sell. Past indicator behavior is not a prediction — educational only, not advice.

About Acumen Pharmaceuticals, Inc.Ā· Biotechnology

source: yahoo

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer's disease. The company was incorporated in 1996 and is headquartered in Newton, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Employees
60
Headquarters
Newton, United States
acumenpharm.com ↗

Fundamentals

No fundamental data is currently available for this listing from our data providers.

Recent news

News sentiment:— Neutral0↑ Ā· 0↓ Ā· 8–
  • 4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day— Neutral
    Zacks Ā· 21 Sept 2026
  • Acumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026— Neutral
    GlobeNewswire Ā· 10 Sept 2026
  • Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences— Neutral
    GlobeNewswire Ā· 02 Sept 2026
  • Acumen Pharmaceuticals Inc (ABOS) (Q2 2026) Earnings Call Highlights: Advancing Sabirnetug ...
— Neutral
GuruFocus.com Ā· 12 Aug 2026
  • Acumen Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary— Neutral
    Moby Ā· 12 Aug 2026
  • Acumen Pharmaceuticals Q2 Earnings Call Highlights— Neutral
    MarketBeat Ā· 12 Aug 2026
  • Sentiment is a keyword-based read of the headline — a rough signal, not advice.